The FINANCIAL — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) on March 8 announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2016. The company will select research partners for the project from among researchers based in Japan.
1. Background
As one aspect of open innovation and the development of a competitive pipeline for the rapid and continuous creation of innovative new drugs, the Daiichi Sankyo Group has operated the collaborative research and grant program TaNeDS since 2011, conducting drug discovery research with domestic academic researchers. In 2013, Daiichi Sankyo’s wholly owned subsidiary, Daiichi Sankyo RD Novare Co., Ltd. (hereafter, RD Novare) joined TaNeDS to help promote the development of technology platforms for the next generation, and from 2016, Daiichi Sankyo’s wholly owned subsidiary, Asubio Pharma Co., Ltd. (hereafter, Asubio Pharma) will also participate in these measures to promote greater drug discovery.
Since 2013, Daiichi Sankyo has sought further drug discovery research possibilities by casting a wide net, even overseas*, to find research themes and technologies that will result in the discovery of new drugs.
Discussion about this post